All news

SPRO: Spero Therapeutics Inc. filed SEC Form 8-K: Leadership Update

Alpha Vantage · Quantisnow · · AI-summarised by FinFlash

Spero Therapeutics (SPRO) announced via an SEC Form 8-K filing a leadership change on its board of directors. Dr. Patrick Vink resigned, effective November 10, 2026, and Dr. Ho, formerly CMO at RAPT, was appointed to the board, receiving cash retainers and an option to purchase 100,000 shares.

Read original source

SPRO company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.